You just read:

ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome

News provided by

ArmaGen, Inc.

Mar 31, 2016, 07:00 ET